Free Trial

Bioventix (LON:BVXP) Stock Price Crosses Below 50-Day Moving Average - Here's Why

Bioventix logo with Medical background

Key Points

  • Bioventix PLC shares have fallen below their 50-day moving average of GBX 2,483.17, reaching a low of GBX 2,400 ($32.35) during trading.
  • The company has a market capitalization of £126.71 million and a significantly high price-to-earnings ratio of 1,637.19.
  • Bioventix specializes in the creation and supply of sheep monoclonal antibodies for various diagnostic applications globally, including thyroid and cardiac health.
  • MarketBeat previews the top five stocks to own by November 1st.

Bioventix PLC (LON:BVXP - Get Free Report) shares passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 2,483.17 ($33.47) and traded as low as GBX 2,400 ($32.35). Bioventix shares last traded at GBX 2,400 ($32.35), with a volume of 9,767 shares traded.

Bioventix Trading Down 1.0%

The firm has a 50-day simple moving average of GBX 2,483.17 and a two-hundred day simple moving average of GBX 2,619.06. The company has a market capitalization of £126.71 million, a price-to-earnings ratio of 1,637.19 and a beta of 0.35.

About Bioventix

(Get Free Report)

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bioventix Right Now?

Before you consider Bioventix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.

While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.